Andere Sprachen BriaCell Therapeutics Corp.

Aktien

A3ES82

CA1079301091

BCT

Markt geschlossen - Toronto S.E. Andere Börsenplätze 21:59:59 15.05.2024			% 5 Tage	% 1. Jan.
2,3 ^CAD	-19,58 %		-25,32 %	-70,51 %

15.05.	BriaCell Therapeutics gibt Preis für $5 Millionen Offering bekannt; Aktien fallen	MT
10.04.	BriaCell 2024 AACR Preclinical Poster bestätigt starke Anti-Krebs-Aktivität von Bria-OTS+? und Bria-PROS+? Klinische Kandidaten für Brust- und Prostatakrebs	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BriaCell Therapeutics Prices $5 Million Offering; Shares Tumble	15.05.
BriaCell Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering	15.05.
BriaCell Therapeutics to Present Bria-IMT Phase 2 Findings at American Society of Clinical Oncology Annual Meeting	24.04.
BriaCell Announces Oral and Poster Presentations at ASCO 2024	24.04.
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+™ and Bria-PROS+™ Clinical Candidates for Breast and Prostate Cancer	10.04.
BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity of Bria-OTS+? and Bria-PROS+? Clinical Candidates for Breast and Prostate Cancer	10.04.
BriaCell to Showcase Latest Bria-IMT Data in Poster Presentations at 2024 AACR	09.04.
BriaCell Showcases Data Demonstrating Unmatched Progression-Free Survival (PFS) and Clinical Efficacy in Antibody-Drug Conjugate (ADC) Resistant and Central Nervous System (CNS) Metastatic Breast Cancer at the 2024 AACR	09.04.
BriaCell Therapeutics : NOTICE OF NO AUDITOR REVIEW OF THE CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS - Form 8-K	02.04.
BriaCell Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	18.03.
BriaCell Receives and Executes Letter of Intent to Advance Clinical Development of Breast and Prostate Cancer Immunotherapies	07.03.
BriaCell to Present Clinical Data in CNS Metastasis and Antibody-Drug Conjugate Resistant Breast Cancer at AACR Conference	06.03.
BriaCell to Present Clinical Data in Central Nervous System (CNS) Metastasis and Antibody-Drug Conjugate (ADC) Resistant Breast Cancer at the 2024 AACR Conference	06.03.
BriaCell Provides Update on Alleged Illegal Trading of Public Securities	27.02.
BriaCell Announces Strong Clinical Data in Breast Cancer Patients	07.02.
BriaCell Therapeutics Corp. Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case	07.02.
BriaCell Announces Strong Clinical Data in Breast Cancer Patients; Reports Another Notable Responder Case	07.02.
Toronto Stocks Rally; Precision Drilling Rises on 4Q Profit Growth	06.02.
Breaking Ground in Prostate Cancer: BriaCell Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates GMP Manufacturing	06.02.
Briacell Therapeutics Corp. Announces Lead Prostate Cancer Candidate Bria-Pros+, Initiates Gmp Manufacturing	06.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BriaCell Therapeutics Corp.

Aktien

A3ES82

CA1079301091

BCT

Andere Sprachen

Filter